Correlation Between the SPhENo-Cardiograph™, a Seismocardiograph Device, and GE Vivid Q, an Echocardiograph, for Known Systemic Timing Intervals (STI)

NCT02636023 | Completed

• 1 other identifier: SPHENO_CLIN_003
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

The study Sponsor, Heart Force Medical Inc. (HFM), has developed a patented medical device called the SPhENo-CardiographTM. The SPhENo-Cardiograph™ provides a non-invasive assessment of the electro-mechanical function of the heart. The electrocardiograph (ECG) represents the waveform of the electrical stimulus to the cardiac muscle. The mechanical actions of the electrical potentials delivered in the ECG are revealed as the seismocardiograph (SCG). The SCG represents the changes in acceleration of the heart during the cardiac cycle. The SCG waveform reflects the ultra-low frequency vibrations of cardiac contraction. These low frequency vibrations are transmitted through the sternum. Using the point of initiation of ventricular contraction on the ECG, the Q wave, with fiduciary points on the synchronous seismocardiograph, it is possible to determine timing events of the cardiac cycle. The timing events of the cardiac cycle during systole are referred to as Systolic Timing Intervals (STI) and comprise the Pre-Ejection Period (PEP) and the Left Ventricular Ejection Time (LVET). The PEP is the time from the Q wave to the Aortic valve opening. The Left Ventricular Eject Time (LVET) is the time between the Aortic Valve opening and closing. The ratio of PEP/LVET in individuals with established heart disease is \> 0.42. It is based on the formula described by Dr Arnold Weissler and first published in Circulation in 1968 (Weissler et al,1968). Weissler et al showed that the PEP/LVET ratio \>0.42 are indicative of a lengthening of the PEP with some marginal shortening of the LVET. This is indicative of pathology associated with the coronary circulation (Ahmed et al, 1972;). This ratio can then be used as part of a non-invasive quantitative assessment of cardiac performance (Lewis et al 1977). Using the SPhENo-CardiographTM, HFM has developed an algorithm to assess heart health that otherwise requires a number of technologies; stethoscope, ECG and Carotid pulse tracing to identify the dicrotic notch or Aortic Valve closure.

Conditions

Cardiovascular Risk Factor

Outcome Measures

Primary Outcomes (4)

• Correlation coefficient ≥0.8 between STI ratio values determined by the SPhENo-Cardiograph™ and an echocardiograph

  1 day

• Correlation coefficient ≥0.8 between PEP values determined by the SPhENo-Cardiograph™ and an echocardiograph

  1 day

• Correlation coefficient ≥0.8 between LVET values determined by the SPhENo-Cardiograph™ and an echocardiograph

  1 day

• Correlation coefficient ≥0.8 between heart rate values determined by the SPhENo-Cardiograph™ and an echocardiograph

  1 day

Secondary Outcomes (6)

• Correlation coefficient ≥0.8 between STI ratio values determined by the SPhENo-Cardiograph™ and a manual analysis

  1 day

• Correlation coefficient ≥0.8 between PEP values determined by the SPhENo-Cardiograph™ and a manual analysis

  1 day

• Correlation coefficient ≥0.8 between LVET values determined by the SPhENo-Cardiograph™ and a manual analysis

  1 day

• Correlation coefficient ≥0.8 between heart rate values determined by the SPhENo-Cardiograph™ and a manual analysis

  1 day

• Safety and tolerability assessed by Adverse event collection

  1 day

Study Arms (1)

SPhENo-Cardiograph / ECG

EXPERIMENTAL

SPhENo-Cardiograph and ECG

Device: SPhENo-Cardiograph

Interventions

SPhENo-Cardiograph DEVICE

SPhENo-Cardiograph

SPhENo-Cardiograph / ECG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to understand the informed consent document
• Willing to participate in study
• Ambulatory volunteer

You may not qualify if:

• Individuals with visible scar(s) or deformity in the test area of the chest
• Non-ambulatory subjects
• Previously diagnosed with life-threatening condition (e.g. cancer)
• Known or diagnosed psychiatric condition
• Enrolled in a concurrent study or trial
• Exercised excessively within the last 4 hours (prior to study visit)
• Consumption of caffeine containing drinks within the previous 4 hours
• Unwilling to sign Informed Consent
• Female subjects who are pregnant, suspected or planning to become pregnant or breast-feeding

Sponsors & Collaborators

• Heart Force Medical Inc.: lead

Study Sites (1)

Boucher Institute of Naturopathic Medicine

New Westminster, British Columbia, V3L 5N8, Canada

Location

Study Officials

• Karrin Fairman Young, ND

  Boucher Institute of Naturopathic Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 22, 2015
• First Posted: December 21, 2015
• Study Start: August 1, 2015
• Primary Completion: August 1, 2015
• Study Completion: August 1, 2015
• Last Updated: February 11, 2016

Record last verified: 2016-02

Locations

CA (1)